Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of Tislelizumab (BGB-A317) plus nab-paclitaxel with or without platinum as first-line treatment in elderly (aged = 70 years) advanced non-small cell lung cancer patients: a single arm, prospective clinical study

Next Previous
X
Search
Trial Profile

Efficacy and safety of Tislelizumab (BGB-A317) plus nab-paclitaxel with or without platinum as first-line treatment in elderly (aged = 70 years) advanced non-small cell lung cancer patients: a single arm, prospective clinical study

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tislelizumab (Primary) ; Carboplatin; Nedaplatin; Paclitaxel
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 09 Aug 2022 Results (n=33) evaluating the efficacy and safety of tislelizumab plus albumin-bound paclitaxel with or without platinum as first-line treatment for advanced NSCLC , presented at the 2022 World Conference on Lung Cancer
    • 04 Aug 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top